Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

Children and adults vaccinated on the recommended hep B series are afforded lifelong protection against the hepatitis B virus (HBV), a highly infectious virus that attacks the liver. Vaccination ...

In April 2025, Vir Biotechnology Inc. announced a phase 1b/2 platform study framework to evaluate the safety and efficacy of ...

The company is dedicated to educating patients, providers, and others on new findings in chronic hepatitis B virus (HBV) infection. Chronic HBV infection is the most common viral infection in ...

Kurnool: With a spike in hepatitis B and hepatitis C virus cases, the Clinical Microbiology wing at Nandyal Government ...

C infection. Methods Patients presenting to a ... Results Patients with hepatitis B (HBV) were more likely to develop HCC at a younger age than patients with hepatitis C (HCV) (HBV-26% under ...

Liver cancer, particularly hepatocellular carcinoma (HCC), has become a major health concern in Uganda. The Uganda Cancer ...

The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an investigational gene editing therapy for adults with chronic hepatitis B.

Viral hepatitis was the most common cause of infectious disease mortality worldwide after tuberculosis in 2024, according to ...

Precision BioSciences (DTIL) announced that the FDA has granted fast track designation for PBGENE-HBV, the company’s lead wholly owned in vivo ...